Amgen, Owkin: cardiovascular risk prediction project
Artificial intelligence (AI) startup Owkin and biotech Amgen have released the results of a three-year project to use AI to more accurately predict cardiovascular risk. Using data from 13,756 patients from Amgen’s FOURIER trial, Owkin trained a machine-learning (ML) algorithm to predict those at higher risk of cardiovascular events; results show ML is more efficient and effective than the statistical models routinely used by clinicians.
Jean-Frédéric Petit-Nivard, senior vice president of commercial and product strategy, said, "We are delighted that our collaboration, which began in 2016, has yielded compelling scientific results that could fundamentally improve patient monitoring and treatment. We look forward to continuing this project with Amgen to translate these scientific findings into clinical applications."